-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text: Ke Zhikang
On the track of psoriatic arthritis, Johnson & Johnson’s Tremfya is a relatively new competitor.
Johnson & Johnson researchers presented the results of the clinical Phase 3b Cosmos trial at the EULAR meeting
Tremfya helped 44.
It seems that the field is not crowded enough.
Since Skyrizi was approved for the treatment of plaque psoriasis in 2019, sales have been stronger than expected.
Another new AbbVie drug, Rinvoq, is a competitor of Pfizer's Xeljanz, and faces delays in the FDA's evaluation of its psoriatic arthritis